PMID- 10789596
OWN - NLM
STAT- MEDLINE
DCOM- 20000721
LR  - 20190915
IS  - 0959-4973 (Print)
IS  - 0959-4973 (Linking)
VI  - 11
IP  - 2
DP  - 2000 Feb
TI  - A comparative pharmacokinetic study of doxorubicin and 4'-epi-doxorubicin in 
      children with acute lymphocytic leukemia using a limited sampling procedure.
PG  - 129-36
AB  - Antraquinone glycosides are an important class of antineoplastic drugs, 
      frequently used for treatment of a variety of malignancies in children. 
      Doxorubicin (Dox) is the most frequently used drug within this class of 
      antineoplastics. 4'-epi-doxorubicin (Epi), a Dox isomer, was developed with the 
      aim of reducing risks for fatal heart toxicity observed with Dox. The aim of the 
      present study was to investigate the pharmacokinetics of Dox and Epi in children 
      with acute lymphocytic leukemia. In total 31 patients (13 females and 18 males; 
      median age 5.4 years; range 0.73-15.3 years) were studied using a simplified 
      sampling procedure. The pharmacokinetic differences of the two drugs were 
      established by their simultaneous administration. The plasma pharmacokinetics of 
      neither Dox nor Epi correlated with the age of the patients. There were no gender 
      differences in dose-normalized maximum concentrations of neither Dox nor of Epi. 
      The inter-patient variation of the dose-normalized maximum concentrations of Dox 
      and Epi is larger among females than among males. The Cmax ratio Dox/Epi was 
      1.39+/-0.19 (mean +/- SD). The pharmacokinetic differences of Dox and Epi in 
      children, although less pronounced than in adults, are still of a magnitude that 
      might be of clinical importance.
FAU - Eksborg, S
AU  - Eksborg S
AD  - Karolinska Pharmacy, Karolinska Hospital, Stockholm, Sweden. 
      stygge.staffan@swipnet.se
FAU - Palm, C
AU  - Palm C
FAU - Bjork, O
AU  - Bjork O
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Anticancer Drugs
JT  - Anti-cancer drugs
JID - 9100823
RN  - 0 (Antineoplastic Agents)
RN  - 3Z8479ZZ5X (Epirubicin)
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - Adolescent
MH  - Antineoplastic Agents/*pharmacokinetics
MH  - Area Under Curve
MH  - Child
MH  - Child, Preschool
MH  - Doxorubicin/*pharmacokinetics
MH  - Epirubicin/*pharmacokinetics
MH  - Female
MH  - Humans
MH  - Infant
MH  - Male
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/*metabolism
EDAT- 2000/05/02 09:00
MHDA- 2000/08/01 11:00
CRDT- 2000/05/02 09:00
PHST- 2000/05/02 09:00 [pubmed]
PHST- 2000/08/01 11:00 [medline]
PHST- 2000/05/02 09:00 [entrez]
AID - 10.1097/00001813-200002000-00010 [doi]
PST - ppublish
SO  - Anticancer Drugs. 2000 Feb;11(2):129-36. doi: 10.1097/00001813-200002000-00010.